Results 31 to 40 of about 16,167 (200)
Mineralocorticoid Receptor Antagonist for Renal Protection
Renal Failure, 2012 The renin-angiotensin system (RAS) plays an important role in the pathophysiology of cardiovascular and renal diseases. In chronic kidney disease (CKD), blockade of RAS by angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) has been shown to reduce proteinuria and retard the progression of renal function deterioration ...
Terry King-Wing, Ma, Cheuk-Chun, Szeto
openaire +2 more sources
Treatment and practical considerations of diabetic kidney disease
Frontiers in Medicine, 2023 Diabetic kidney disease (DKD) is a complication of diabetes that can lead to kidney failure. Over the years, several drugs have been developed to combat this disease.
Yara Bilen +5 more
doaj +1 more source
Regulation of Klotho Production by Mineralocorticoid Receptor Signaling in Renal Cell Lines
BiomoleculesThrough the mineralocorticoid receptor, aldosterone controls extracellular volume and arterial blood pressure by stimulating Na+ absorption and K+ secretion in epithelial cells of the kidney, colon, and several glands.
Elena Kohm +2 more
doaj +1 more source
Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy
Case Reports in Ophthalmology, 2015 Overactivation of mineralocorticoid receptor pathways has been implicated in the pathophysiology of central serous chorioretinopathy (CSCR). Recently, mineralocorticoid receptor antagonists such as eplerenone have demonstrated success in treating ...
Kapil G. Kapoor, Alan L. Wagner
doaj +1 more source
Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease [PDF]
Clinical Journal of the American Society of Nephrology, 2020 Ten years ago, I presented an outline for a study aiming to prevent diabetic kidney disease (DKD), with early intervention in subjects with type 2 diabetes and high risk for DKD assessed by a urinary proteomic–based biomarker, at Kidney Week hoping for positive feedback.
openaire +3 more sources
Albanian Journal of Trauma and Emergency Surgery, 2022 Inappropriate activation of the mineralocorticoid receptor (MR) plays a significant role in developing hypertension, the development of cardiac pathological changes, and chronic kidney disease (CKD), where death related to cardiovascular (CV) causes is ...
Eqerem Hasani +2 more
doaj +1 more source
Kidney Research and Clinical Practice, 2018 Background: Previous studies have shown that aldosterone antagonists have a proteinuria-lowering effect in patients with proteinuria and progressive proteinuric disease not adequately controlled by the use of angiotensin receptor blockers (ARBs ...
Byung Chul Yu +6 more
doaj +1 more source
Molecular Metabolism, 2021 Objective: Carbonyl reductase 1 (Cbr1), a recently discovered contributor to tissue glucocorticoid metabolism converting corticosterone to 20β-dihydrocorticosterone (20β-DHB), is upregulated in adipose tissue of obese humans and mice and may contribute ...
Rachel M.B. Bell +18 more
doaj +1 more source
Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases [PDF]
Hypertension, 2015 Cardiac and renal diseases remain major challenges for healthcare systems in developed countries and commonly coexist, with a disorder in the heart or kidney often leading to secondary dysfunction or injury in the other organ. Indeed, the term cardiorenal syndrome has been introduced to describe the broad spectrum of disease involving both the heart ...
Johann, Bauersachs +2 more
openaire +2 more sources
New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
Терапевтический архив, 2021 Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to
Natalia A. Dragomiretskaya +3 more
doaj +1 more source